Page 153 - Veterinary Toxicology, Basic and Clinical Principles, 3rd Edition
P. 153

120 SECTION | I General




  VetBooks.ir  for an x% response (BMDLx), or a similar POD should  Maximum Residue Level
             be used. The BMD/BMDL approach is just one of a num-
                                                                All new pharmacologically active substances that are
             ber of approaches that have been developed to refine the
             ability to characterize the toxicological hazard of a veteri-  intended for use in food animals must have MRLs estab-
                                                                lished prior to licensing. Termed tolerances in the United
             nary drug (Edler et al., 2002).
                                                                States, they are defined as the maximum concentration of
                The safe concentration is the maximal allowable con-
                                                                a residue of a pharmacologically active substance that
             centration of total residues of toxicologic concern in edi-
                                                                may be permitted in food of animal origin (expressed in
             ble tissue and is calculated from the ADI and considers
                                                                mg/kg or μg/kg on a fresh-weight basis). It is based on
             the weight of an average person and the amount of meat,
                                                                the type and amount of residue considered to be without
             milk, or eggs consumed daily by a high-consuming
                                                                any toxicological hazard for human health as expressed
             individual.
                                                                by the ADI. Other relevant public risks and aspects relat-
                The identification of the residue profile and its decline
                                                                ing to food technology, good practice in the use of veteri-
             in the treated animal, resulting in the setting of MRLs,
                                                                nary drugs, and analytical methodologies are also
             enables the exposure assessment and risk characterization
                                                                considered when establishing MRLs. In the EU those
             to be determined. Additionally the theoretical maximum
                                                                drugs for which an MRL value should be established are
             daily intake (TMDI) is calculated. The TMDI is an esti-
                                                                governed by Regulation (EC) No. 470/2009 (EC, 2009a),
             mate of dietary intake based on multiplying the MRL by
                                                                repealing Council Regulation (EEC) No. 2377/90 (EEC,
             the average food consumption for each commodity (i.e., it
                                                                1990). According to Article 6 of this regulation the scien-
             is assumed that a person with a body weight of 60 kg con-
                                                                tific RA shall consider the metabolism and depletion of
             sumes every day over a lifetime 500 g of mammalian or
                                                                pharmacologically active substances in relevant animal
             poultry “meat” (muscle, liver, kidney, fat) or 300 g of fish
                                                                species, the type of residues and the amount thereof that
             plus 1500 g of milk plus 100 g of eggs plus 20 g honey)
                                                                may be ingested by human beings over a lifetime without
             and then summing the products (Table 7.6) (EMA-CVMP
                                                                an appreciable health risk expressed in terms of ADI.
             and WHO, 1989). It is assumed that all the previous tis-
                                                                Alternative approaches to ADI may also be used. The RA
             sues and products contain residues at a concentration
                                                                is concerned with the following: (1) the type and amount
             equivalent to the MRL every day.
                                                                of residue considered not to present a safety concern for
                Article 14(7) of Regulation (EC) No. 470/2009 (EC,
                                                                human health; (2) the risk of toxicological, pharmacologi-
             2009a) states “where it appears necessary for the protec-
                                                                cal, or microbiological effects in human beings; and
             tion of human health, the classification shall include con-
                                                                (3) residues that occur in food of plant origin or that
             ditions and restrictions for the use or application of a
                                                                come from the environment. If the metabolism and deple-
             pharmacologically active substance used in veterinary
                                                                tion of the substance cannot be assessed, the scientific RA
             medicinal products that is subject to a MRL, or for which
                                                                may take into account monitoring data or exposure data.
             no MRL has been set” (e.g., not for use in animals from
                                                                  A variety of toxicological evaluations are performed
             which milk or eggs are produced for human consumption)
                                                                to establish the safety of veterinary drug residues in
             (see Table 7.7).
                                                                human food. The standard approach to assessing the
                The Table 7.8, “prohibited substances,” includes sub-
                                                                safety of residues in foodstuffs intended for human con-
             stances considered to be unsafe on the grounds of public
                                                                sumption is based on the determination of the ADI on
             health (Regulation 37/2010, Table 7.2 of Annex) (EU, 2010).
                                                                which, in turn, MRLs are based. The establishment of a
               TABLE 7.6 Standard Food Basket
               Mammals           Poultry                        Fish                            Bees
               Muscle  0.300 kg  Muscle               0.300 kg  Muscle and skin in natural  0.300 kg  Honey  0.20 kg
                                                                proportions
               Fat     0.050 kg a  Fat and skin in natural  0.090 kg
                                 proportions
               Liver   0.100 kg  Liver                0.100 kg
               Kidney  0.050 kg  Kidney               0.010 kg
               Milk    1.500 kg  Eggs                 0.100 kg
               a
                Fat and skin in natural proportions for pigs.
   148   149   150   151   152   153   154   155   156   157   158